Metabolomic and lipidomic analyses reveal phosphatidylcholine-lysophosphatidylcholine axis alterations in sorafenib-persistent hepatocellular carcinoma.
Metabolic reprogramming and lipid remodeling are increasingly recognized as key processes underlying carcinogenesis and cancer treatment failure. The liver, as a central hub for lipid metabolism and homeostasis, is particularly susceptible to such alterations. Accordingly, hepatocellular carcinoma (HCC) exhibits extens...